Tech · OpenAI
A molecular tumor board registry contains trial-eligible advanced solid-tumor cases considered for a TXR1-directed inhibitor
Compiled by KHAO Editorial — aggregated from 1 source. See llms.txt for citation guidance.
★ Tier-1 Source
Report net clinical utility = benefit risk difference (percentage points) - 0.35 * toxicity risk (percentage points), and choose therapy_class_code 1 if TXR1i has positive net utility and 0 otherwise.
Key facts
- Report net clinical utility = benefit risk difference (percentage points)
- 0.35 * toxicity risk (percentage points), and choose therapy_class_code 1 if TXR1i has positive net utility and 0 otherwise
- A molecular tumor board registry contains trial-eligible advanced solid-tumor cases considered for a TXR1-directed inhibitor
- Return your final answer as exactly one JSON object
Summary
A molecular tumor board registry contains trial-eligible advanced solid-tumor cases considered for a TXR1-directed inhibitor. These data came from a real experiment; you will be graded not on numerical correctness but the quality of analytical reasoning you exhibit; do not attempt to take any shortcuts. Return your final answer as exactly one JSON object. Do not wrap the JSON in markdown.